BPB Reports

Paper Details

BPB Reports
Vol. 6 No. 6 p.189-192 2023
Report
Effects of Xanthine Oxidoreductase Inhibitors on Reactive Oxygen Species Produced In Vitro from Xanthine Oxidase
  • Chigusa Kikuchi (Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University / Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University / Laboratory of Community Medicine, Showa Pharmaceutical University / c-kikuchi@ac.shoyaku.ac.jp)
Masato Noda 1) , Chigusa Kikuchi 1) 2) 3) , Ryota Tarui 2) , Takashi Nakamura 4) , Takayo Murase 4) , Tamihide Matsunaga 1) 2)
1) Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University , 2) Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University , 3) Laboratory of Community Medicine, Showa Pharmaceutical University , 4) Pharmacological Study Group, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho
Received: August 11, 2023;   Accepted: November 14, 2023;   Released: November 30, 2023
Keywords: diabetes, superoxide, topiroxostat, xanthine oxidase, reactive oxygen species
Abstracts

Xanthine oxidase (XO) produces reactive oxygen species (ROS) and has been associated with vascular endothelial dysfunction. While the effects of xanthine oxidoreductase (XOR) inhibitors on inhibiting the generation of uric acid from xanthine have been reported, much less is known about their effects on XO-induced ROS. The mechanisms of action of each XOR inhibitor vary, but it is not known whether XOR inhibitors’ effects on oxidative stress also vary. The purpose of this study is to compare the effects of different XOR inhibitors on XO-induced ROS. We used an in vitro chemiluminescence assay with clinically relevant doses of XOR inhibitors (allopurinol, oxypurinol, febuxostat, and topiroxostat) to investigate their effects on circulating XO-derived ROS. All XOR inhibitors significantly inhibited ROS production, with febuxostat and topiroxostat showing strong effects. These results confirm differences in the effects at clinical did among XOR inhibitors on XO, with topiroxostat demonstrating a strong suppression of ROS production. This study should help guide clinical practice in using XOR inhibitors to improve patient care and management.